Jimmy Bechtel talks with Darcy Forman, COO of Lightship, about how hybrid site models can reduce operational risk in clinical trials. They discuss matching visit types to the right setting (clinic, home, or mobile), lessons learned from the pandemic's rapid shift to decentralized trials, and how to maintain strong investigator oversight across different delivery models. Darcy shares practical insights on what it takes to implement flexible approaches successfully, including the importance of investigator buy-in, standardized processes, and building trust-based relationships between sites, sponsors, and CROs.